Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF BUS/STRAT OFFICER | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 74,430 |
Ending reported balance
After 2026-08-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-14 · Exercise / conversion · Acquired 32,710 · Balance 107,140 Row 2 · 2026-08-14 · Sale · Disposed 32,710 · Balance 74,430 |
| Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.02 · Expires 2029-02-20 | Direct | 0 |
Reported balance
After 2026-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-14 · Exercise / conversion · Disposed 32,710 · Balance 0 F1: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 32,710 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001762951-26-000006 · form4-08182026_050811.xml · derivative · entry 3 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,710 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 32,710 | $250.00 | $8,177,500.00 |
DisclosureSEC source: 0001762951-26-000006 · form4-08182026_050811.xml · nonDerivative · entry 2 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,430 Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 32,710 | $79.02 | $2,584,744.20 |
DisclosureSEC source: 0001762951-26-000006 · form4-08182026_050811.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:10 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 12,874 | $232.08 | $2,987,797.92 |
DisclosureSEC source: 0001762951-26-000004 · form4-03032026_060301.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,430 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 20,312 | $0.00 Strike: $230.04 | $0.00 |
DisclosureSEC source: 0001762951-26-000002 · form4-02202026_060205.xml · derivative · entry 5 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,312 Underlying: Common Stock · 20,312 shares Expires 2036-02-17 F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001762951-26-000002 · form4-02202026_060205.xml · nonDerivative · entry 4 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,304 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001762951-26-000002 · form4-02202026_060205.xml · nonDerivative · entry 3 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,082 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001762951-26-000002 · form4-02202026_060205.xml · nonDerivative · entry 2 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,910 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 23:35 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 13,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001762951-26-000002 · form4-02202026_060205.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,278 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 10,061 | $198.59 | $1,998,013.99 |
DisclosureSEC source: 0001415889-25-021280 · form4-08072025_050802.xml · nonDerivative · entry 2 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,247 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.56 to $198.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,234.17 | $198.27 | $641,238.89 |
DisclosureSEC source: 0001415889-25-021280 · form4-08072025_050802.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,308 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.26 to $198.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This reflects shares acquired pursuant to a dividend reinvestment plan. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 11,230 | $205.02 | $2,302,374.60 |
DisclosureSEC source: 0001415889-25-006585 · form4-03042025_050318.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,018 Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 23,437 | $0.00 Strike: $192.86 | $0.00 |
DisclosureSEC source: 0001415889-25-004457 · form4-02182025_050205.xml · derivative · entry 5 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 23,437 shares Expires 2035-02-12 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028. F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,813 on February 13, 2026, 7,812 on February 13, 2027, and 7,812 on February 13, 2028. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 4 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,248 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 3 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,074 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 2 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,440 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004457 · form4-02182025_050205.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,920 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 21,082 | $176.30 | $3,716,756.60 |
DisclosureSEC source: 0001415889-24-008970 · form4-03222024_050301.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,903 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.26 to $176.35, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 16,771 | $178.99 | $3,001,841.29 |
DisclosureSEC source: 0001415889-24-006156 · form4-03012024_050303.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,985 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 21,433 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004423 · form4-02202024_100216.xml · derivative · entry 5 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,433 Underlying: Common Stock · 21,433 shares Expires 2034-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,145 on February 15, 2025, 7,144 on February 15, 2026, and 7,144 on February 15, 2027. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 4 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,756 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 3 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,122 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 2 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,602 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 22,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004423 · form4-02202024_100216.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,560 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,912 | $154.72 | $450,544.64 |
DisclosureSEC source: 0001415889-23-016990 · form4-12282023_051202.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,903 F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.72 to $154.73, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:51 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 2,355 | $85.42 | $201,164.10 |
DisclosureSEC source: 0001179110-20-002852 · edgar.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,149 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:04 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 72,013 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002136 · edgar.xml · derivative · entry 2 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,013 Underlying: Common Stock · 72,013 shares Expires 2030-02-19 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,005 on February 20, 2021, 24,004 on February 20, 2022, and 24,004 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:04 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002136 · edgar.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,504 F1 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 902 | $88.54 | $79,863.08 |
DisclosureSEC source: 0001179110-20-000295 · edgar.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,188 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 20:08 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon stock, $0.01 par value | 7,525 | $66.19 | $498,057.18 |
DisclosureSEC source: 0001179110-19-009960 · edgar.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,090 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 32,710 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002362 · edgar.xml · derivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,710 Underlying: Common Stock · 32,710 shares Expires 2029-02-20 F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:52 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000444 · edgar.xml · nonDerivative · entry 1 Donoghoe Nicholas · CIK 0001762951 · SVP, Enterprise Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,565 F1 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 1,855 on 01/02/2020, 1,855 on 01/02/2021, and 1,855 on 01/02/2022, and include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.